We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo

By LabMedica International staff writers
Posted on 03 Aug 2017
Print article
Image: The VITROS NephroCheck test (Photo courtesy of Ortho Clinical Diagnostics).
Image: The VITROS NephroCheck test (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA) was among over 750 exhibitors who displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services.

Ortho’s in vitro diagnostics products and services for the clinical laboratory and immunohematology communities include blood typing products, sophisticated testing technologies, automation, information management and interpretation tools. At the 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from August 1-3, Ortho presented 10 scientific posters highlighting its focus on immunodiagnostics, with discussions on acute kidney injury (AKI), insulin and infectious diseases.

The products on display in Ortho's booth at AACC 2017 included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions, and the ORTHO VISION and ORTHO VISION Max Analyzers. The company also highlighted the NephroCheck test, a risk assessment tool for predicting AKI.

Visitors to Ortho's booth were able to see what is possible in a re-imagined lab and make tangible connections between the work accomplished in the lab and patients' wellbeing. The company’s R&D team shared its vision for the future of in vitro diagnostics in its Innovation Lab. The attendees were able to test their skills using real-time dashboard tools and also learned more about working with medical practitioners to help improve cardiac outcomes and help reduce the severity of AKI.

“AACC is a wonderful opportunity for us to engage with members of the lab community and hear their feedback on our products, both current and in development,” said Alex Socárras, chief commercial officer for Ortho.

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Human Chorionic Gonadotropin Test
Humasis hCG Combo
New
Cytomegalovirus Assay
Alethia CMV

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.